TABUK PHARMACEUTICALS SIGNS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT WITH AENOVA HOLDING FOR DICLOFENAC SODIUM AND OMEPRAZOL FIXED DOSE COMBINATION PELLETS
Tabuk Pharmaceutical Manufacturing Company “Tabuk”, one of the leading pharmaceutical companies in the Middle East and North Africa region (MENA) region, has entered into an exclusive license and supply agreement with Aenova Holding, under which Aenova Holding granted to Tabuk an exclusive license to market and sell Aenova’s fixed dose combination pellets for patients at high risk for upper gastrointestinal (GI) ulceration who require nonsteroidal anti-inflammatory drugs (NSAIDs) in Saudi Arabia, the Gulf Countries, North Africa, and the Middle East.
This project is aligned with one of Tabuk Pharmaceuticals’ main strategic objectives; to expand its offering of novel medicines in Saudi Arabia & the MENA region and to reach more patients with an expanded portfolio of innovative ingredients.
This agreement has been established as a product-line extension to the lead product Diclofenac dual release pellets that is available for patients in KSA and MENA since 2003.
Dr. Rana Azzam, Senior VP of Business Development commented , “We are pleased to add Aenova’s unique product to our growing portfolio, This illustrates our commitment to leverage our MENA-wide footprint, and help address a large unmet medical need in the region”.
Aenova’s once daily fixed dose combination is indicated for symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis (Morbus Bechterew) in patients with a previous history or who are at risk of developing NSAID associated gastric and/or duodenal ulcers.
This unique combination will target patients who have real issue of gastric ulcers from using NSAID and will bring a solution of one Capsule having the medications together which will ensure patient compliance and acceptability to the product.